Moderna’s updated COVID-19 shot, set to be deployed this fall, induced a “significant boost” of antibodies of the EG.5 omicron subvariant, nicknamed the Eris strain, according to preliminary clinical trial data from the company.
When Moderna filed for authorization from the Food and Drug Administration (FDA) for its updated shot earlier this year, it cited how its vaccine…